Close Topic Options

Psoriasis Vulgaris

Psoriasis Vulgaris

This cutaneous condition: known as Psoriasis Vulgaris, can be Discussed here.

Persons finding themselves or loved ones distressed in their lives because of Psoriasis vulgaris (Chronic stationary psoriasis, Plaque-like psoriasis) may like to share how they cope in order to help others world-wide searching for experiences.

Vulgaris Psoriasis

FDA approves TALTZ (Ixekizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

On March 22, 2016, the U.S. Food and Drug Administration (FDA) approved TALTZ (Ixekizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Approved Recommended TALTZ Dosage and Administration

TALTZ is administered by subcutaneous (SC) injection. The approved recommended dosage is 160 mg (Two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering TALTZ. Consider completion of all age appropriate immunizations prior to initiating therapy with TALTZ. Avoid use of live vaccines in patients treated with TALTZ. Ref. Source 4e.